10,000 Shares in iShares Biotechnology ETF $IBB Acquired by CVS HEALTH Corp

CVS HEALTH Corp acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,000 shares of the financial services provider’s stock, valued at approximately $2,105,000. iShares Biotechnology ETF comprises 0.5% of CVS HEALTH Corp’s investment portfolio, making the stock its 28th largest position.

Other institutional investors have also bought and sold shares of the company. Kaydan Wealth Management Inc. raised its stake in shares of iShares Biotechnology ETF by 3.9% in the third quarter. Kaydan Wealth Management Inc. now owns 1,363 shares of the financial services provider’s stock valued at $287,000 after buying an additional 51 shares during the period. Carter Financial Group INC. grew its stake in shares of iShares Biotechnology ETF by 2.2% during the 2nd quarter. Carter Financial Group INC. now owns 2,423 shares of the financial services provider’s stock worth $461,000 after acquiring an additional 53 shares during the period. Parallel Advisors LLC increased its holdings in iShares Biotechnology ETF by 8.8% in the 1st quarter. Parallel Advisors LLC now owns 744 shares of the financial services provider’s stock worth $126,000 after acquiring an additional 60 shares during the last quarter. Apollon Wealth Management LLC increased its holdings in iShares Biotechnology ETF by 0.7% in the 3rd quarter. Apollon Wealth Management LLC now owns 8,178 shares of the financial services provider’s stock worth $1,722,000 after acquiring an additional 60 shares during the last quarter. Finally, Global Assets Advisory LLC increased its holdings in iShares Biotechnology ETF by 3.1% in the 3rd quarter. Global Assets Advisory LLC now owns 2,082 shares of the financial services provider’s stock worth $432,000 after acquiring an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of iShares Biotechnology ETF stock opened at $218.14 on Thursday. iShares Biotechnology ETF has a 52-week low of $159.68 and a 52-week high of $222.29. The stock’s 50-day simple moving average is $208.98 and its 200 day simple moving average is $186.54.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, September 18th. Stockholders of record on Tuesday, September 15th were paid a $0.0112 dividend. The ex-dividend date was Tuesday, September 15th. This is a negative change from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. This represents a $0.04 annualized dividend and a dividend yield of 0.0%.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.